Navigation Links
Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products

SCHAUMBURG, Ill. and MORRISTOWN, N.J., May 4 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, and Actavis Inc., a leading global generic pharmaceutical manufacturer, have launched an exclusive collaboration to develop and market a select group of specialty injectable medications for the United States.

Under the agreement, Actavis will develop, obtain U.S. Food and Drug Administration approval, and supply the products, which Sagent will market in the United States. Financial terms of the agreement have not been disclosed.

"Actavis' impressive injectable pipeline, substantial development and supply capabilities and excellent record of execution make Actavis an outstanding partner for Sagent," said Jeffrey M. Yordon, Sagent's chief executive officer, founder and chairman of the board. "This collaboration complements Sagent's strategy by quickly adding products to our marketed portfolio and we look forward to working with Actavis to expand our collective portfolio."

Doug Boothe, chief executive officer of Actavis Inc., said the strategic collaboration with Sagent will enable consumers in the United States to benefit from the company's global expertise in developing and manufacturing specialty injectable products.

"By combining our injectable pipeline with Sagent's and partnering with their sales and marketing team, we have increased our potential to serve the U.S. market for these valuable products beyond what either of our companies could have achieved independently," Boothe said. Headquartered in Morristown, N.J., Actavis Inc. is the U.S. subsidiary of Iceland-based Actavis Group.  

About Sagent Pharmaceuticals

Sagent Pharmaceuticals is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.  Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.

To Discover Injectables Excellence™ and learn more about Sagent, please visit

About Actavis Inc.

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one quarter of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing facilities in Elizabeth, NJ; Little Falls, NJ; Totowa, NJ; and Lincolnton, NC. Actavis also has research and development facilities in Owings Mills, MD and Sunrise, FL; and a packaging facility in Totowa, NJ. Please visit for more information.

SOURCE Sagent Pharmaceuticals, Inc.; Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
2. Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP
3. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
4. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
5. Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
6. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
7. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
8. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
9. Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
10. Reportlinker Adds The Outlook for Pharmaceuticals in Western Europe
11. ISTA Pharmaceuticals to Present at the Ninth Annual JMP Securities Research Conference
Post Your Comments:
(Date:11/25/2015)... 25, 2015  The American Academy of Pediatrics ... and the March of Dimes cheered today,s signature ... Infants Act of 2015 (S.799), which takes ... born exposed to drugs, such as opioids, and ... all three organizations have worked together leading advocacy ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... Ltd. (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical ... the simultaneous treatment of various clinical conditions, today announced ... of 3,158,900 American Depository Shares ( ADSs ), each ... to purchase up to 3,158,900 ADSs. The ADSs and ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... 29, 2015 , ... Effective immediately, every single IguanaMed scrub style will be ... Target is offering a “Buy One Scrub Set, Get the 2nd Scrub Set 50% ... IguanaMed at a discounted price. , IguanaMed’s mission is to outfit every ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may not ... from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there is ... the expense of having to replace NuvaRings more often than necessary. As such, it ...
(Date:11/28/2015)... CA (PRWEB) , ... November 28, 2015 , ... Pixel ... fully customizable media panels to choose from, the possibilities are endless. Users have full ... more. With the ProPanel: Pulse masking effects, users are sure to get heads to ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse ... the findings on the website. Click here to read the details now. ... who were treated with chemotherapy followed by EPP surgery. Among the 106 patients who ...
Breaking Medicine News(10 mins):